Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity

Rhinomed Limited

ABN

12 107 903 159

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director

Ron Dewhurst

Date of last notice

4 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest

  • (1) Indirect

  • (2) Direct

  • (3) Indirect

  • (4) Indirect

Nature of indirect interest (including registered holder)

  • (1) Director related

  • (2) N/A

  • (3) Director related entity

  • (4) Director related entity

Date of change

  • (1) N/A

  • (2) 19 April 2022

  • (3.a) 13 April 2022

  • (3.b) 19 April 2022

(4) 19 April 2022

No. of securities held prior to change

(1) 2,000,000 - UNLISTED OPTIONS EXP

29/11/2023 @ $0.2998

  • (2) 3,000,000 - ORDINARY FULLY PAID SHARES

  • (3) 7,284,680 - ORDINARY FULLY PAID SHARES

  • (4) 7,565,320 - ORDINARY FULLY PAID SHARES

+ Seechapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

Class

(1) UNLISTED OPTIONS EXP 29/11/2023 @

$0.2998

  • (2) ORDINARY FULLY PAID SHARES

  • (3) ORDINARY FULLY PAID SHARES

  • (4) ORDINARY FULLY PAID SHARES

Number acquired

  • (1) NIL

  • (2) 303,951 - ORDINARY FULLY PAID SHARES

  • (3.a) 150,000 - ORDINARY FULLY PAID SHARES

  • (3.b) 738,063 - ORDINARY FULLY PAID SHARES

(4) 766,496 - ORDINARY FULLY PAID SHARES

Number disposed

  • (1) NIL

  • (2) NIL

  • (3.a) NIL

  • (3.b) NIL

(4) NIL

Value/Consideration

  • (1) N/A

  • (2) $57,751 - ORDINARY FULLY PAID SHARES

  • (3.a) $37,125 - ORDINARY FULLY PAID SHARES

  • (3.b) $140,232 - ORDINARY FULLY PAID SHARES

(4) $145,634 - ORDINARY FULLY PAID SHARES

No. of securities held after change

(1) 2,000,000 - UNLISTED OPTIONS EXP

29/11/2023 @ $0.2998

  • (2) 3,303,951 - ORDINARY FULLY PAID SHARES

  • (3) 8,172,743 - ORDINARY FULLY PAID SHARES

  • (4) 8,331,816 - ORDINARY FULLY PAID SHARES

Nature of change

  • (1) N/A

  • (2) Institutional Entitlement Offer @ $0.19

  • (3.a) On market

  • (3.b) Institutional Entitlement Offer @ $0.19

(4) Institutional Entitlement Offer @ $0.19

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract

N/A

Nature of interest

N/A

Name of registered holder (if issued securities)

N/A

Date of change

N/A

No. and class of securities to which interest related prior to change

N/A

Interest acquired

N/A

Interest disposed

N/A

Value/Consideration

N/A

Interest after change

N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?

No

If so, was prior written clearance provided to allow the trade to proceed during this period?

N/A

If prior written clearance was provided, on what date was this provided?

N/A

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Rhinomed Limited published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 05:03:09 UTC.